Sorafenib (Sorafenib Tosylate) Patent Expiration, LOE Window & CMS Spending

Sorafenib (Sorafenib Tosylate) by Multi-Source Generic Manufacturers: Multi-Source Generic Molecule, 5 AB generics, $27.8M 2024 CMS Part D & Medicaid spend, and $10,874 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMulti-Source Generic Manufacturers
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$27.8M
2024 Medicare Part D Spend$21.3M
2024 Medicaid Spend$6.4M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($10,874 intro WAC)